Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

NCT02889510 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication liraglutide on lung function in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 76 people

Who can join Ages 40–65 · all sexes

Timeline Started 2016-10 · est. completion 2019-12

Where 6 sites · Spain

What this study is testing ClinicalTrials.gov NCT02889510 ↗

Description as written by the study sponsor.

Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in significant amounts in the lung, it could be hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced pulmonary function

Treatments tested

liraglutide Drug

7-week subcutaneous liraglutide once daily
placebo Drug

7-week subcutaneous placebo once daily

Main thing measured	Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)
Sponsor	Lecube, Albert, M.D.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02889510 ↗